Graefen M - Search Results

1

External validation of a preoperative nomogram for prediction of the risk of recurrence after radical prostatectomy.

Isbarn H, Karakiewicz PI, Walz J, Ahyai SA, Steuber T, Haese A, Budäus L, Schlomm T, Eichelberg C, Heuer R, Heinzer H, Huland H, Graefen M, Chun FK. Isbarn H, et al. Among authors: graefen m. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):788-92. doi: 10.1016/j.ijrobp.2009.05.066. Epub 2009 Oct 8. Int J Radiat Oncol Biol Phys. 2010. PMID: 19818565

2

Surgical therapy for localized prostatic carcinoma.

Noldus J, Hammerer P, Graefen M, Huland H. Noldus J, et al. Among authors: graefen m. J Cancer Res Clin Oncol. 1997;123(3):180-4. doi: 10.1007/BF01214671. J Cancer Res Clin Oncol. 1997. PMID: 9119884

3

Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience.

Heinzer H, Graefen M, Noldus J, Hammerer P, Huland H. Heinzer H, et al. Among authors: graefen m. Urol Int. 1997;59(1):30-3. doi: 10.1159/000283013. Urol Int. 1997. PMID: 9313321

4

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.

Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Haese A, et al. Among authors: graefen m. J Urol. 1997 Dec;158(6):2188-92. doi: 10.1016/s0022-5347(01)68192-8. J Urol. 1997. PMID: 9366341

5

Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas.

Heinzer H, Hammerer P, Graefen M, Huland H. Heinzer H, et al. Among authors: graefen m. Eur Urol. 1998;33(1):86-90. doi: 10.1159/000019516. Eur Urol. 1998. PMID: 9471046 Clinical Trial.

6

Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy.

Graefen M, Hammerer P, Michl U, Noldus J, Haese A, Henke RP, Huland E, Huland H. Graefen M, et al. Urology. 1998 Mar;51(3):437-42. doi: 10.1016/s0090-4295(97)00608-0. Urology. 1998. PMID: 9510349

7

[Development of tumor selection based on pathological stage in clinically localized prostate carcinoma].

Noldus J, Graefen M, Hammerer P, Henke RP, Huland H. Noldus J, et al. Among authors: graefen m. Urologe A. 1998 Mar;37(2):195-8. doi: 10.1007/s001200050173. Urologe A. 1998. PMID: 9563134 German.

8

[Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia].

Lange I, Hammerer P, Knabbe C, Graefen M, Schmahl M, Huland H. Lange I, et al. Among authors: graefen m. Urologe A. 1998 Mar;37(2):199-202. doi: 10.1007/s001200050174. Urologe A. 1998. PMID: 9563135 German.

9

The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.

Noldus J, Graefen M, Huland E, Busch C, Hammerer P, Huland H. Noldus J, et al. Among authors: graefen m. J Urol. 1998 Jun;159(6):2004-7; discussion 2007-8. doi: 10.1016/S0022-5347(01)63227-0. J Urol. 1998. PMID: 9598507

10

Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.

Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Conrad S, et al. Among authors: graefen m. J Urol. 1998 Jun;159(6):2023-9. doi: 10.1016/S0022-5347(01)63234-8. J Urol. 1998. PMID: 9598511

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

962 results

Search Page

Filters